Peptide

Vesugen

Also known as

KED peptide · KED · Lys-Glu-Asp · Lysyl-glutamyl-aspartic acid · H-Lys-Glu-Asp-OH · vascular bioregulator · Vezugen (Russian transliteration) · Vesogen (common misspelling) · T-38 (research designation) · Khavinson vascular tripeptide · vascular cytogen (Khavinson class)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

KED vessel peptide	A synthetic three-amino-acid bioregulator discussed for circulation and the lining of blood vessels. A pump does not demonstrate a rebuilt vessel.
Separate identities and forms	Vesugen/KED differs from Ventfort's tissue-peptide mixture and Cartalax/AED. Capsules, drops, sprays and research vials are also different exposures.

Notes

KED means lysine–glutamate–aspartate. These three amino acids form the defined peptide in Khavinson's bioregulator research. The proposed target is the endothelium, the cell lining inside blood vessels. The theory concerns cell regulation over time; a pump does not demonstrate that a vessel has been rebuilt. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation (Official context · Accessed 2026-09-30)

Vesugen, Ventfort and Cartalax are different identities. Vesugen is the synthetic KED sequence; Ventfort is a vessel-tissue peptide mixture, while Cartalax is AED, a cartilage-related peptide. Capsules, lingual drops, nasal sprays and research vials also differ. 'Vessel-targeted' describes the research idea, not an injection into a blood vessel. Experience with Vesugen (Personal report · Accessed 2026-09-30) · Bioregulators – Capsules vs SubQ? (Personal report · Accessed 2026-09-30)

Source context — Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation: Research-group review summarizing cell/model work, not an independent human efficacy or PK trial. The review's blanket no-side-effects/allergy wording is not adopted. Source kind is supporting formal context, not government approval.

Source context — Experience with Vesugen: Concentration only; spray volume, daily dose, course length and independent product verification absent. Later speculation about supplier does not prove impurity.

Source context — Bioregulators – Capsules vs SubQ?: No capsule mass stated. OP also tried Pinealon; no later Vesugen injection outcome visible. Comments claiming superior injection absorption are opinions.

What people notice

Circulation and pumps	Some report warmer extremities, easier walking/cardio or more visible veins. A preserved injection account also used tadalafil; these impressions do not prove arterial repair.
Sexual-flow and vein claims	Erection-related flow is a goal. One oral user claimed varicose-vein improvement after earlier ablation, without verified reversal measurements.
No noticeable change	A capsule user noticed nothing after ten days; a nasal user noticed no cardio or erection improvement. A later successful injection result was not established for either.

Notes

Circulation, pumps and training comfort. A leg-circulation commenter described improvement after prolonged sitting. The preserved injection account describes prominent veins, slightly easier cardio, recovery and higher Apple Watch HRV while also using tadalafil. Warmer extremities and easier walking appear in the wider record; none establishes arterial repair. Vesugen: leg-circulation discussion (Personal report · Accessed 2026-09-30)

Better veins can come with other agents. The preserved October 2024 account used 2 mg every morning alongside tadalafil; a reply also mentioned Vilon. A newer oral creator likewise credits pumps and vascularity while stacking. These are separate subjective accounts, not proof of new vessel formation or demonstrated synergy. Vesugen: vascular health & morning wood (Personal report · Accessed 2026-09-30)

Erection-related flow and longevity interest. These are recurring goals, not assured effects. An oral user separately claimed major varicose-vein improvement after earlier ablation, whereas a nasal user seeking cardio and ED improvements noticed nothing. Visible veins, erections and wearable scores measure different things. What has been your experience with peptides? (Personal report · Accessed 2026-09-30) · Experience with Vesugen (Personal report · Accessed 2026-09-30)

kaamkerr oral Vesugen/varicose-vein comment and adjacent follow-up What has been your experience with peptides? (Personal report · Accessed 2026-09-30)

No change is reported with both capsules and spray. The ten-day capsule user planned injections but the opened replies do not establish a later injection result. The 2 mg/mL nasal user noticed no cardio or ED effect. Neither shows that every oral or nasal formulation fails, or that injections will succeed. Bioregulators – Capsules vs SubQ? (Personal report · Accessed 2026-09-30) · Experience with Vesugen (Personal report · Accessed 2026-09-30)

Source context — Vesugen: leg-circulation discussion: Uncontrolled report; strength/form not explicit in morning/night reply. Separate 5 mg suggestion has unclear route and no demonstrated outcome. Some replies deleted.

Source context — Vesugen: vascular health & morning wood: Commercial creator article with sourcing section and heavy stack. Personal report does not validate endothelial rebuilding, universal benefit or tadalafil/Vilon synergy. Not counted as independently verified X content. Article-derived prose kept short.

Source context — What has been your experience with peptides?: Subjective comparison to prior ablation, no images, dose, course or diagnostic measurements; no proof of reversal or replacement for treatment. Other commenters' peptide effects are not attributed to Vesugen.

Doses people talk about

SubQ daily discussion	0.5–2 mg total daily appears in a dose thread. Actual accounts include 2 mg each morning and a separate 1 mg/day for 20 days with Cartalax after FGF-18.
Higher stacked account	One user reported 5 mg twice daily, totaling 10 mg/day for 20 days, alongside Cartalax, Pinealon, BPC and TB. Route was not explicit; this is not a validated upper band.
Oral counts	Tables list 1–2 capsules daily or once/twice daily, with varying fills. Capsule counts and marketed capsule mass do not establish pure peptide milligrams.
Lingual drop charts	5–6 drops, about 0.25–0.35 mL, three or four times daily, or 10–12 drops twice daily, appear in different guides. Product-specific mass is not established by drop counts.
Nasal concentration	2 mg/mL is one user's spray label. Missing spray volume and frequency leave the daily amount unknown.

Notes

SubQ: 0.5–2 mg total daily appears in a dose thread. A commenter proposed dividing 2 mg into two administrations. Separate actual accounts used 2 mg every morning and 1 mg/day for 20 days alongside Cartalax and FGF-18. Preserved charts also list 0.5–1 mg daily for 10–30 days and 1–2 mg daily for ten days. Vesugen Peptide Dose? (Community discussion · Accessed 2026-09-30) · Peptides for arthritis? – page 3 (Personal report · Accessed 2026-09-30)

Cataceous update near page lines 449–467; 20-day Vesugen course after FGF-18, other agents and subjective assessment Peptides for arthritis? – page 3 (Personal report · Accessed 2026-09-30)

High amounts are separate claims. The dose-thread commenter suggests 4–5 mg/day for very high blood pressure; that is unsupported advice, not a treatment. Another stack user reports 5 mg twice daily, totaling 10 mg/day for 20 days, with Cartalax, Pinealon, BPC and TB. Route is not explicit in that reply; pain relief cannot isolate Vesugen. Vesugen Peptide Dose? (Community discussion · Accessed 2026-09-30) · Cartalax & BPC-157/TB-500 Blend Stack (Personal report · Accessed 2026-09-30)

Capsule counts do not establish peptide milligrams. A circulated Reddit table lists 1–2 capsules daily; older retail notes list 1–2 capsules once or twice daily, sometimes described as about 10 mg per capsule. Formulation and fill vary. The adverse oral account took capsules twice daily without stating milligrams. A creator reports 4 mg/day orally, a different product claim. Peptide & Research Compound Table 2026 – Updated (Community guide · Accessed 2026-09-30) · Vesugen: vascular health & morning wood (Personal report · Accessed 2026-09-30)

Drops and sprays have different missing details. Preserved lingual guides list 5–6 drops (about 0.25–0.35 mL) three or four times daily, or 10–12 drops twice daily. Oral timing talk differs: with meals, 5–10 minutes before meals, or empty-stomach preference. The nasal nonresponse report names 2 mg/mL; missing spray volume and frequency leave daily dose unknown. Experience with Vesugen (Personal report · Accessed 2026-09-30)

Oral mass ambiguity: Some product lines list different mg-per-capsule or multi-component fills; ‘1–2 caps’ is not automatically equal across brands. [community]

Source context — Vesugen Peptide Dose?: Anonymous advice and family-experience claim; no measured PK, blood-pressure data or precise onset. Safety assurance and high-BP treatment suggestion are rejected. Relative timestamps not converted to dates.

Source context — Peptides for arthritis? – page 3: Many co-interventions; joint-pain account, not clean Vesugen circulation response. Uncontrolled and unverified. Derived article prose restricted to essential course and attribution.

Source context — Cartalax & BPC-157/TB-500 Blend Stack: Extreme self-reported amounts; reply does not explicitly state route or verify material. OP's different blend ratio and route cannot be assigned to respondent. No imaging or controlled outcome.

Source context — Peptide & Research Compound Table 2026 – Updated: User-created chart with vendor links and associated guide/calculator promotion; dosing convention, not a trial or firsthand response. Vesugen vial row does not explicitly state route. Unrelated regulatory assertions not used.

Half-life, onset & duration

Felt onset	No reliable shared starting day. One commenter says quick without a day; days 4–10 and 10–20 are older checkpoints.
Felt duration	One person described a few-hour peak, not a measured benefit window. Slight pumps after stopping have no stated duration; weeks 2–8 afterward is broader lore.
Half-life	Human route-specific clearance is not established. Thirty minutes is an app assumption; other pages say minutes or hours without a matching human measurement.

Notes

No reliable shared starting day. One dose-thread commenter says effects were quick without giving a day. Older notes place warmth or recovery around days 4–10 and review changes near days 10–20; these are circulated checkpoints. One capsule user reported no noticeable effects after ten days, while the adverse account worsened within five. Vesugen Peptide Dose? (Community discussion · Accessed 2026-09-30) · Bioregulators – Capsules vs SubQ? (Personal report · Accessed 2026-09-30)

A few-hour peak is one person's account. The dose-thread commenter felt a full amount hit hard and preferred splitting it. That account does not establish how long vascular benefits last. Another preserved reply described slight pumps after stopping without a duration; weeks 2–8 post-course is broader community lore, not a measured window. Vesugen Peptide Dose? (Community discussion · Accessed 2026-09-30)

Thirty minutes is an app assumption, not measured human clearance. BioHack Track models 0.5 hours; PeptideDosing says 'minutes,' while older community notes guess hours. None supplies a route-specific human measurement. A user's few-hour peak and a once-daily schedule cannot resolve that disagreement or establish half-life. Vesugen – Half-Life & Dose Range (Community guide · Accessed 2026-09-30) · Vesugen 20 mg Vial Dosage Protocol (Community guide · Accessed 2026-09-30) · Vesugen Peptide Dose? (Community discussion · Accessed 2026-09-30)

Source context — Vesugen – Half-Life & Dose Range: Pre-filled decay model is an assumption, not a human measurement. Commercial tracking tool, not a first-person experiment.

Source context — Vesugen 20 mg Vial Dosage Protocol: Protocol compilation with no human PK citation. Internal supplies table is inconsistent with its dose/cycle; arithmetic and safety claims not adopted. Promotional/clinical-sounding presentation is not efficacy evidence.

Cycles people discuss

Short blocks	A forum log used 20 days. Older injection calendars span 10–30 days, sometimes 4–6 weeks; oral/drop blocks often span 20–30 days.
Longer guide pattern	8–12-week daily ramps and 4–8 weeks off appear in commercial guides. They are competing conventions rather than an escalation requirement.
Repeats and sequences	3–6-month breaks and 2–4 annual courses circulate. About a month of Vesugen followed by two months of Ventfort is another calendar, without proof of an optimal or safe cycle.

Notes

Short blocks and months-long breaks. The forum log used 20 days. Preserved injection calendars span 10–30 days, sometimes 4–6 weeks; oral/drop blocks usually span 20–30 days. Breaks of 3–6 months, occasional 1–3-month gaps and 2–4 annual courses circulate. Age charts suggest 1–2 courses at 25–35, two at 40–45 and three at 50-plus; these are unvalidated conventions. Peptides for arthritis? – page 3 (Personal report · Accessed 2026-09-30)

Eight to twelve weeks is a competing guide pattern. A Reddit table lists 500 mcg–2 mg daily over 8–12 weeks. PepGuru describes once-daily SubQ phases of 500 mcg in weeks 1–2, 1 mg in weeks 3–4, 1.5 mg in weeks 5–8 and 2 mg in weeks 9–12, with 4–8 weeks off. These are commercial guide conventions, not an escalation requirement. Peptide & Research Compound Table 2026 – Updated (Community guide · Accessed 2026-09-30) · Vesugen Protocol (Community guide · Accessed 2026-09-30)

Vesugen then Ventfort is a circulated sequence. Older calendars describe about one month of Vesugen followed by two months of Ventfort. Other users stack them or rotate pineal, thymus and organ peptides. Year-round use, longer 12–16-week ramps and 30–60-day shop cycles also appear; no pattern establishes the best cycle or long-term safety. Peptide Bioregulators – Experiences? (Community opinion · Accessed 2026-09-30)

Source context — Vesugen Protocol: Commercial guide with tracking accounts, calculator and supplier ecosystem. It labels convention as community-reported but does not substantiate a success rate or dose-response. Reconstitution instructions excluded.

Source context — Peptide Bioregulators – Experiences?: Class-level and multiple-product accounts. One commenter reverses cytogen/cytomax terminology; that error is not copied. Does not prove enhanced absorption of every other peptide.

Stacks

Ventfort	Oral Ventfort alongside injectable Vesugen, or Vesugen followed by Ventfort, appears in vascular-stack talk. They are different products, not equal peptide amounts.
Tadalafil and Vilon	The preserved vein/pump accounts include tadalafil, Vilon or both. They do not demonstrate synergy or identify which ingredient caused a change.
Multi-organ combinations	Cardiogen/Chelohart, Epitalon/Pinealon and thymus/immune peptides appear in broader organ calendars, alongside other rotating bioregulators.
Joint-recovery stacks	Cartalax after FGF-18 and larger BPC/TB-containing stacks appear in recovery reports. Neither establishes cartilage regrowth or a Vesugen-only effect.

Notes

Ventfort (primary pair): Vesugen as cytogen ‘fast’ vascular phase then Ventfort cytomax for longer support — or oral Ventfort alongside injectable KED in forum posts. [community]

Tadalafil and Vilon in the blood-flow posts: The Oct 2024 vein report and later pump posts pair Vesugen with tadalafil (Cialis), Vilon, or both. That is what those people were also taking. It is not a studied combination. [anecdote]

Cardiogen / Chelohart: Vessel peptide + heart-muscle bioregulator for ‘full CV kit’ talk. [community]

Epitalon (± Pinealon): Longevity ‘base’ — pineal/telomere narratives plus vascular cytogen. [community]

Thymalin / Vilon / Crystagen: Immune-axis peers in classic multi-organ Khavinson calendars (Khavinson-style ‘big three’ often framed pineal + thymus + circulatory). [community]

Pinealon or Semax-class: Cognition + cerebral perfusion stack logic. [community]

Multi-organ rotations: Cartalax, Chonluten, Ovagen, etc., on rotating organ calendars rather than lifelong solo daily Vesugen. [community]

Joint-recovery stacks are not isolated vascular results. The ExcelMale history combined Vesugen with Cartalax after FGF-18, later adding other agents. A Reddit heavy-stack user claimed enough pain relief to cancel surgery. Their stories preserve the recovery interest, but neither establishes cartilage regrowth or which ingredient mattered. Forum recommendations to make all other bioregulators work better remain opinions. Peptides for arthritis? – page 3 (Personal report · Accessed 2026-09-30) · Cartalax & BPC-157/TB-500 Blend Stack (Personal report · Accessed 2026-09-30) · Peptide Bioregulators – Experiences? (Community opinion · Accessed 2026-09-30)

Watch for

Weakness and mental changes	An oral user stopped on day five after weakness, brain fog and mood changes, then described symptoms weeks later. Sudden weakness or speech trouble needs urgent medical assessment.
Other unwanted effects	Stomach upset, bloating, headache, fatigue and injection-site redness, sting or itch are in the earlier notes; their frequency and cause are unknown.
Interactions and product risks	Tadalafil, blood-pressure drugs and blood thinners lack established Vesugen interaction guidance. Identity, contamination, unit errors and pregnancy/long-term safety remain unresolved.

Notes

Unwanted effects can outlast a short course in a report. The oral account stopped on day five but described weakness and altered mood about two weeks later, with a later comment saying mental baseline remained changed. There is no dependable single-dose duration or proof that after-course changes reflect peptide remaining in blood.

Weakness, brain fog and mood changes are reported. The oral account includes grip problems, irritability, trouble speaking and depressed mood. Older notes also include stomach upset, bloating, headache, fatigue and injection-site redness, sting or itch. Frequency and causality are unknown. Sudden weakness, speech trouble, chest pain or breathing difficulty need urgent medical assessment.

Stacks and unknown product quality complicate safety. Tadalafil, blood-pressure drugs, anticoagulants and antiplatelets do not have established Vesugen interaction guidance. Cell-growth findings prompt theoretical cancer concerns, not proof of cancer causation. Pregnancy, breastfeeding and significant kidney/liver disease lack adequate safety information. Mislabeling, contamination and mg/mcg confusion remain material risks; prescribed cardiovascular care cannot be replaced by these reports. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation (Official context · Accessed 2026-09-30)

Full notes

Vesugen is a short synthetic peptide discussed for circulation, gym pumps, visible veins and erection-related blood flow. Some people describe better circulation or easier cardio; others notice nothing or feel worse. Its vascular reputation does not establish that it repairs blood vessels or treats cardiovascular disease.

What Vesugen is

KED means lysine–glutamate–aspartate. These three amino acids form the defined peptide in Khavinson's bioregulator research. The proposed target is the endothelium, the cell lining inside blood vessels. The theory concerns cell regulation over time; a pump does not demonstrate that a vessel has been rebuilt. Official context
Vesugen, Ventfort and Cartalax are different identities. Vesugen is the synthetic KED sequence; Ventfort is a vessel-tissue peptide mixture, while Cartalax is AED, a cartilage-related peptide. Capsules, lingual drops, nasal sprays and research vials also differ. 'Vessel-targeted' describes the research idea, not an injection into a blood vessel. Community Personal report Personal report

What people hope to notice

Circulation, pumps and training comfort. A leg-circulation commenter described improvement after prolonged sitting. The preserved injection account describes prominent veins, slightly easier cardio, recovery and higher Apple Watch HRV while also using tadalafil. Warmer extremities and easier walking appear in the wider record; none establishes arterial repair. Personal report Community
Erection-related flow and longevity interest. These are recurring goals, not assured effects. An oral user separately claimed major varicose-vein improvement after earlier ablation, whereas a nasal user seeking cardio and ED improvements noticed nothing. Visible veins, erections and wearable scores measure different things. Personal report Personal report Community

Doses people discuss

Reported amounts describe discussion, not instructions. SubQ means beneath the skin; 1,000 mcg equals 1 mg. Capsule mass, liquid concentration and injected peptide mass cannot be exchanged directly.

SubQ: 0.5–2 mg total daily appears in a dose thread. A commenter proposed dividing 2 mg into two administrations. Separate actual accounts used 2 mg every morning and 1 mg/day for 20 days alongside Cartalax and FGF-18. Preserved charts also list 0.5–1 mg daily for 10–30 days and 1–2 mg daily for ten days. Reddit r/peptidebioregulators Community Personal report
High amounts are separate claims. The dose-thread commenter suggests 4–5 mg/day for very high blood pressure; that is unsupported advice, not a treatment. Another stack user reports 5 mg twice daily, totaling 10 mg/day for 20 days, with Cartalax, Pinealon, BPC and TB. Route is not explicit in that reply; pain relief cannot isolate Vesugen. Reddit r/peptidebioregulators Personal report
Capsule counts do not establish peptide milligrams. A circulated Reddit table lists 1–2 capsules daily; older retail notes list 1–2 capsules once or twice daily, sometimes described as about 10 mg per capsule. Formulation and fill vary. The adverse oral account took capsules twice daily without stating milligrams. A creator reports 4 mg/day orally, a different product claim. Community guide Community Personal report
Drops and sprays have different missing details. Preserved lingual guides list 5–6 drops (about 0.25–0.35 mL) three or four times daily, or 10–12 drops twice daily. Oral timing talk differs: with meals, 5–10 minutes before meals, or empty-stomach preference. The nasal nonresponse report names 2 mg/mL; missing spray volume and frequency leave daily dose unknown. Community Personal report

Half-life

Thirty minutes is an app assumption, not measured human clearance. BioHack Track models 0.5 hours; PeptideDosing says 'minutes,' while older community notes guess hours. None supplies a route-specific human measurement. A user's few-hour peak and a once-daily schedule cannot resolve that disagreement or establish half-life. Community guide Community guide Community Reddit r/peptidebioregulators

Onset: when people notice a change

No reliable shared starting day. One dose-thread commenter says effects were quick without giving a day. Older notes place warmth or recovery around days 4–10 and review changes near days 10–20; these are circulated checkpoints. One capsule user reported no noticeable effects after ten days, while the adverse account worsened within five. Reddit r/peptidebioregulators Community Personal report

Duration: how long a change lasts

A few-hour peak is one person's account. The dose-thread commenter felt a full amount hit hard and preferred splitting it. That account does not establish how long vascular benefits last. Another preserved reply described slight pumps after stopping without a duration; weeks 2–8 post-course is broader community lore, not a measured window. Reddit r/peptidebioregulators Community
Unwanted effects can outlast a short course in a report. The oral account stopped on day five but described weakness and altered mood about two weeks later, with a later comment saying mental baseline remained changed. There is no dependable single-dose duration or proof that after-course changes reflect peptide remaining in blood. Community

Cycles and breaks people discuss

Short blocks and months-long breaks. The forum log used 20 days. Preserved injection calendars span 10–30 days, sometimes 4–6 weeks; oral/drop blocks usually span 20–30 days. Breaks of 3–6 months, occasional 1–3-month gaps and 2–4 annual courses circulate. Age charts suggest 1–2 courses at 25–35, two at 40–45 and three at 50-plus; these are unvalidated conventions. Personal report Community
Eight to twelve weeks is a competing guide pattern. A Reddit table lists 500 mcg–2 mg daily over 8–12 weeks. PepGuru describes once-daily SubQ phases of 500 mcg in weeks 1–2, 1 mg in weeks 3–4, 1.5 mg in weeks 5–8 and 2 mg in weeks 9–12, with 4–8 weeks off. These are commercial guide conventions, not an escalation requirement. Community guide Community guide
Vesugen then Ventfort is a circulated sequence. Older calendars describe about one month of Vesugen followed by two months of Ventfort. Other users stack them or rotate pineal, thymus and organ peptides. Year-round use, longer 12–16-week ramps and 30–60-day shop cycles also appear; no pattern establishes the best cycle or long-term safety. Community Reddit r/Peptides

What deserves caution

Weakness, brain fog and mood changes are reported. The oral account includes grip problems, irritability, trouble speaking and depressed mood. Older notes also include stomach upset, bloating, headache, fatigue and injection-site redness, sting or itch. Frequency and causality are unknown. Sudden weakness, speech trouble, chest pain or breathing difficulty need urgent medical assessment. Community
Stacks and unknown product quality complicate safety. Tadalafil, blood-pressure drugs, anticoagulants and antiplatelets do not have established Vesugen interaction guidance. Cell-growth findings prompt theoretical cancer concerns, not proof of cancer causation. Pregnancy, breastfeeding and significant kidney/liver disease lack adequate safety information. Mislabeling, contamination and mg/mcg confusion remain material risks; prescribed cardiovascular care cannot be replaced by these reports. Community Official context

What supporting research can show

Cell markers explain the hypothesis, not the result people feel. An originating-group review discusses endothelin-1, connexins, SIRT1, Ki67, VEGF and p53 in vascular-cell models. These help explain the gene-expression pitch; they do not demonstrate human vessel repair, stroke prevention, longer life or a safe injectable amount. Official context
Small human reports are not a dose or duration standard. An indexed abstract describes 41 patients with vasculogenic ED and improved penile arterial flow. Older notes circulate one capsule daily for a month, 53–61% flow improvement, a seven-point score change and four-month follow-up. The opened abstract supplies neither capsule strength nor those details; they remain secondhand formal claims, not community outcomes. Official context Community
Animal numbers stay with their species and endpoint. A rat hypoxia experiment examined survival under oxygen deprivation, while other mouse claims concern prolonged disease-model exposure. These animal settings cannot establish human onset, half-life, effective amounts or benefit duration. Animal context Community

Community experiences and disagreements

Better veins can come with other agents. The preserved October 2024 account used 2 mg every morning alongside tadalafil; a reply also mentioned Vilon. A newer oral creator likewise credits pumps and vascularity while stacking. These are separate subjective accounts, not proof of new vessel formation or demonstrated synergy. Community Personal report
No change is reported with both capsules and spray. The ten-day capsule user planned injections but the opened replies do not establish a later injection result. The 2 mg/mL nasal user noticed no cardio or ED effect. Neither shows that every oral or nasal formulation fails, or that injections will succeed. Personal report Personal report
Leg improvement and adverse oral experiences coexist. One older commenter described improved leg circulation using one in the morning and one at night, without identifying strength or proving varicose-vein reversal. The oral adverse account reported fewer noticeable palpitations alongside persistent mental and physical problems. A beneficial change in one symptom does not erase the unwanted effects. Personal report Community
Joint-recovery stacks are not isolated vascular results. The ExcelMale history combined Vesugen with Cartalax after FGF-18, later adding other agents. A Reddit heavy-stack user claimed enough pain relief to cancel surgery. Their stories preserve the recovery interest, but neither establishes cartilage regrowth or which ingredient mattered. Forum recommendations to make all other bioregulators work better remain opinions. Personal report Personal report Reddit r/Peptides